Mechanisms of small-molecule binding to intrinsically disordered proteins

Biochemical Society Transactions

Volumn 40, Issue 5, 2012, Pages 1004-1008

  Cuchillo, Rémi ^a   Michel, Julien ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

synuclein; Amyloid peptide (A ); C Myc; Intrinsically disordered protein; Small molecule

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; MYC PROTEIN;

ALZHEIMER DISEASE; GENE EXPRESSION; GENE OVEREXPRESSION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BINDING SITES; DRUG DESIGN; HUMANS; MOLECULAR DYNAMICS SIMULATION; PROTO-ONCOGENE PROTEINS C-MYC; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866671396     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20120086     Document Type: Review

References (43)

1. Uversky, V.N. and Dunker, A.K. (2010) Understanding protein non-folding. Biochim. Biophys. Acta 1804, 1231-1264
2. Hansen, J.C., Lu, X., Ross, E.D. and Woody, R.W. (2006) Intrinsic protein disorder, amino acid composition, and histone terminal domains. J. Biol. Chem. 281, 1853-1856
3. Uversky, V.N. (2011) Intrinsically disordered proteins from A to Z. Int. J. Biochem. Cell Biol. 43, 1090-1103
4. Radivojac, P., Iakoucheva, L.M., Oldfield, C.J., Obradovic, Z., Uversky, V.N. and Dunker, A.K. (2007) Intrinsic disorder and functional proteomics. Biophys. J. 92, 1439-1456
5. Iakoucheva, L.M., Brown, C.J., Lawson, J.D., Obradovic, Z. and Dunker, A.K. (2002) Intrinsic disorder in cell-signaling and cancer-associated proteins. J. Mol. Biol. 323, 573-584
6. Campen, A., Williams, R.M., Brown, C.J., Meng, J., Uversky, V.N. and Dunker, A.K. (2008) TOP-IDP-scale: a new amino acid scale measuring propensity for intrinsic disorder. Protein Pept. Lett. 15, 956-963
7. Dyson, H.J. and Wright, P.E. (2002) Coupling of folding and binding for unstructured proteins. Curr. Opin. Struct. Biol. 12, 54-60
8. Uversky, V.N. (2011) Multitude of binding modes attainable by intrinsically disordered proteins: a portrait gallery of disorder-based complexes. Chem. Soc. Rev. 40, 1623-1634
9. Uversky, V.N., Oldfield, C.J. and Dunker, A.K. (2008) Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu. Rev. Biophys. 37, 215-246
10. Chene, P. (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 3, 102-109
11. Shangary, S. and Wang, S. (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 49, 223-241
12. Khoury, K., Popowicz, G.M., Holak, T.A. and Doemling, A. (2011) The p53-MDM2/MDMX axis: a chemotype perspective. Med. Chem. Commun. 2, 246-260
13. Metallo, S.J. (2010) Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 14, 481-488
14. Yin, X.Y., Giap, C., Lazo, J.S. and Prochownik, E.V. (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22, 6151-6159
15. Pickhardt, M., Gazova, Z., von Bergen, M., Khlistunova, I., Wang, Y.P., Hascher, A., Mandelkow, E.M., Biernat, J. and Mandelkow, E. (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628-3635
16. Cohen, T., Frydman-Marom, A., Rechter, M. and Gazit, E. (2006) Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 45, 4727-4735
17. Follis, A.V., Hammoudeh, D.I., Wang, H., Prochownik, E.V. and Metallo, S.J. (2008) Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem. Biol. 15, 1149-1155
18. Lebel, R., McDuff, F.-O., Lavigne, P. and Grandbois, M. (2007) Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box sequences on the hTERT promoter. Biochemistry 46, 10279-10286
19. Hammoudeh, D.I., Follis, A.V., Prochownik, E.V. and Metallo, S.J. (2009) Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 131, 7390-7401
20. Follis, A.V., Hammoudeh, D.I., Daab, A.T. and Metallo, S.J. (2009) Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg. Med. Chem. Lett. 19, 807-810
21. Michel, J. and Cuchillo, R. (2012) The impact of small molecule binding on the energy landscape of the intrinsically disordered protein c-Myc. PLoS ONE 7, e41070
22. Wisnewski, H.M. and Terry, R.D. (1973) Reexamination of the pathogenesis of the senile plaque. Prog. Neuropathol. 2, 1-26
23. Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N. and Beyreuther, K. (1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4, 2757-2763
24. Bharadwaj, P.R., Dubey, A.K., Masters, C.L., Martins, R.N. and Macreadie, I.G. (2009) Aβ aggregation and possible implications in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 13, 412-421
25. Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H.A. and Herms, J. (2006) Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 26, 7212-7221
26. Coles, M., Bicknell, W., Watson, A.A., Fairlie, D.P. and Craik, D.J. (1998) Solution structure of amyloid β-peptide(1-40) in a water-micelle environment: is the membrane-spanning domain where we think it is? Biochemistry 37, 11064-11077
27. Carter, M.D., Simms, G.A. and Weaver, D.F. (2010) The development of new therapeutics for Alzheimer's disease. Clin. Pharmacol. Ther. 88, 475-486
28. McLaurin, J., Kierstead, M.E., Brown, M.E., Hawkes, C.A., Lambermon, M.H.L., Phinney, A.L., Darabie, A.A., Cousins, J.E., French, J.E., Lan, M.F. et al. (2006) Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12, 801-808
29. McLaurin, J., Golomb, R., Jurewicz, A., Antel, J.P. and Fraser, P.E. (2000) Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit Aβ-induced toxicity. J. Biol. Chem. 275, 18495-18502
30. Groenning, M. (2010) Binding mode of Thioflavin T and other molecular probes in the context of amyloid fibrils-current status. J. Chem. Biol. 3, 1-18
31. Convertino, M., Vitalis, A. and Caflisch, A. (2011) Disordered binding of small molecules to Aβ(12-28). J. Biol. Chem. 286, 41578-41588
32. Ito, M, Johansson, J, Strömberg, R. and Nilsson, L. (2012) Effects of ligands on unfolding of the amyloid β-peptide central helix: mechanistic insights from molecular dynamics simulations. PLoS ONE 7, e30510
33. Li, G., Rauscher, S., Baud, S. and Pomes, R. (2012) Binding of inositol stereoisomers to model amyloidogenic peptides. J. Phys. Chem. B 116, 1111-1119
34. Spillantini, M.G., Schmidt, M.L., Lee, V.M.Y., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840
35. Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M.Y., Trojanowski, J.Q. and Iwatsubo, T. (1998) Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884
36. Conway, K.A., Rochet, J.C., Bieganski, R.M. and Lansbury, P.T. (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346-1349
37. Norris, E.H., Giasson, B.I., Hodara, R., Xu, S.H., Trojanowski, J.Q., Ischiropoulos, H. and Lee, V.M.Y. (2005) Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280, 21212-21219
38. Herrera, F.E., Chesi, A., Paleologou, K.E., Schmid, A., Munoz, A., Vendruscolo, M., Gustincich, S., Lashuel, H.A. and Carloni, P. (2008) Inhibition of α-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS ONE 3, e3394
39. Lendel, C., Bertoncini, C.W., Cremades, N., Waudby, C.A., Vendruscolo, M., Dobson, C.M., Schenk, D., Christodoulou, J. and Toth, G. (2009) On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of α-synuclein with Congo Red and lacmoid. Biochemistry 48, 8322-8334
40. Li, J., Zhu, M., Manning-Bog, A.B., Di Monte, D.A. and Fink, A.L. (2004) Dopamine and l-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 18, 962-964
41. Wang, H.B., Hammoudeh, D.I., Follis, A.V., Reese, B.E., Lazo, J.S., Metallo, S.J. and Prochownik, E.V. (2007) Improved low molecular weight Myc-Max inhibitors. Mol. Cancer Ther. 6, 2399-2408
42. Harrington, C., Rickard, J.E., Horsley, D., Harrington, K.A., Hindley, K.P., Riedel, G., Theuring, F., Meng Seng, K. and Wischik, C.M. (2008) Methylthioninium chloride (MTC) acts as a tau aggregation inhibitor (TAI) in a cellular model and reverses tau pathology in transgenic mouse models of Alzheimer's disease. Alzheimer's Dementia 4, 120-121
43. Bulic, B., Pickhardt, M., Mandelkow, E.-M. and Mandelkow, E. (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59, 276-289